<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119513">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02135770</url>
  </required_header>
  <id_info>
    <org_study_id>HLDS01</org_study_id>
    <nct_id>NCT02135770</nct_id>
  </id_info>
  <brief_title>Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis</brief_title>
  <official_title>Randomized Control Trial to Assessed the Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <authority>Indonesia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is a clinical syndrome which infection trigger systemic inflammatory response.
      Uncontrolled inflammatory process leads to multiple organ dysfunction and cause early
      mortality in severe sepsis. Unfractionated heparin is anticoagulant that widely used either
      for  DVT prophylaxis and treatment of disseminated intravascular coagulation. Heparin also
      have anti inflammatory effect trough downregulates nuclear factor kappa B and tumor necrosis
      factor alpha.

      Aim of this study is to determine effects of low dose unfractionated heparin treatment on
      inflammation in severe sepsis patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>inflammation</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>determine effects of low dose unfractionated heparin treatment on  nuclear factor kappa B, inhibitor kappa B kinase  and tumor necrosis factor-alpha.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical outcome</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>determine impact of low dose unfractionated heparin on mortality and improvement APACHE II score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Severe Sepsis With Septic Shock</condition>
  <condition>Severe Sepsis Without Septic Shock</condition>
  <arm_group>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose unfractionated Heparin 10 unit/kgBW/hour continuous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline packed in same form with trial drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin</intervention_name>
    <description>10 unit/kgBW/hour continuous infusion for 72 hours</description>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe sepsis and septic shock define by revised Sepsis Criteria (2001)

          -  Within 48 hour diagnose sepsis

          -  Agree to participate

        Exclusion Criteria:

          -  Pregnancy and lactation

          -  Severe thrombocytopenia, platelet less than 30.000/mm3

          -  Bleeding or high risk of major bleeding

          -  During anticoagulant treatment

          -  After thrombolytic treatment

          -  Decompensated chronic liver diseases

          -  Chronic kidney diseases on dialysis treatment

          -  During high dose corticosteroid treatment

          -  HIV with CD4 count below 50/mm3

          -  Indication for high dose heparin treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Khie Chen Lie, MD</last_name>
    <phone>+62213904190</phone>
    <email>chen_tropik@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Cipto Mangunkusumo General Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khie Chen Lie, MD</last_name>
      <phone>+62213904190</phone>
      <email>chen_tropik@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>May 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Khie Chen Lie</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>heparin</keyword>
  <keyword>sepsis</keyword>
  <keyword>inflammation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
